6/14/2016: UPDATED INFORMATION AND MULTIPLE BLOGS I HAVE SINCE WRITTEN SHOW THAT WHOLE PLANT CANNABIS IS NOT RECTALLY ABSORBED. THC CAN BE RECTALLY ABSORBED BUT ONLY IF BONDED TO A SEPARATE MOLECULE, SUCH AS HEMI-SUCCINATE.
MANY PATIENTS USE HIGH DOSES OF THC BY THE RECTAL ROUTE TO AVOID PSYCHOACTIVITY. THE REASON THERE IS NO PSYCHOACTIVITY IS BECAUSE IT IS NOT ABSORBED.
Below is a fairly well done study in rats showing that Rectal Absorption was fairly similar to intra-peritoneal absorption and that oral absorption was not particularly helpful. I found this last part surprising, but we are clearly in need of more rectally absorbed cannabis product.
HERE IS THE ARTICLE SUMMARY
Compounds of Cannabis sativa are known to exert anti-inflammatory properties, some of them without inducing psychotropic side effects. Cannabidiol (CBD) is such a side effect-free phytocannabinoid that improves chemically induced colitis in rodents when given intraperitoneally. Here, we tested the possibility whether rectal and oral application of CBD would also ameliorate colonic inflammation, as these routes of application may represent a more appropriate way for delivering drugs in human colitis.
Colitis was induced in CD1 mice by trinitrobenzene sulfonic acid. Individual groups were either treated with CBD intraperitoneally (10 mg/kg), orally (20 mg/kg) or intrarectally (20 mg/kg). Colitis was evaluated by macroscopic scoring, histopathology and the myeloperoxidase (MPO) assay.
Intraperitoneal treatment of mice with CBD led to improvement of colonic inflammation. Intrarectal treatment with CBD also led to a significant improvement of disease parameters and to a decrease in MPO activity while oral treatment, using the same dose as per rectum, had no ameliorating effect on colitis.
The data of this study indicate that in addition to intraperitoneal application, intrarectal delivery of cannabinoids may represent a useful therapeutic administration route for the treatment of colonic inflammation.
Copyright © 2012 S. Karger AG, Basel.